The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis - Research portal of Justus Liebig University Giessen:

Meeting Abstract

The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis

Authors list: Mueller-Ladner, Ulf; Gaffney, Karl; Jadon, Deepak; Freudensprung, Ulrich; Addison, Janet

Publication year: 2021

Pages: 1689-1691

Journal: Arthritis & Rheumatology

Volume number: 73

ISSN: 2326-5191

eISSN: 2326-5205

Conference: ACR Convergence Conference

Publisher: Wiley

Citation Styles

Harvard Citation style: Mueller-Ladner, U., Gaffney, K., Jadon, D., Freudensprung, U. and Addison, J. (2021) The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis, Arthritis & Rheumatology, 73, pp. 1689-1691

APA Citation style: Mueller-Ladner, U., Gaffney, K., Jadon, D., Freudensprung, U., & Addison, J. (2021). The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis. Arthritis & Rheumatology. 73, 1689-1691.